Advertisement

Topics

Tenofovir alafenamide in chronic hepatitis B: Added benefit not proven, data incomplete

20:00 EDT 4 Jul 2017 | AAAS

(Institute for Quality and Efficiency in Health Care) No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.

Original Article: Tenofovir alafenamide in chronic hepatitis B: Added benefit not proven, data incomplete

NEXT ARTICLE

More From BioPortfolio on "Tenofovir alafenamide in chronic hepatitis B: Added benefit not proven, data incomplete"

Advertisement
Quick Search
Advertisement
Advertisement